Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic hormone Sensitive Prostate Cancer (mHSPC)
The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC.
Patients must have metastatic prostate cancer with histologically or cytologically confirmed adenocarcinoma (current or prior biopsy of the prostate and/or metastatic site) Patients must have an ECOG performance status of 0 to 2 Patients must be adults >= 18 years of age Patients must have evidence of PSMA-positive disease as seen on a 68Ga-PSMA-11 PET/CT scan
Exclusion Criteria:
Patients with rapidly progressing tumor that requires urgent exposure to taxane-based chemotherapy Patients with CNS metastases that are neurologically unstable, symptomatic, or receiving corticosteroids for the purpose of maintaining neurologic integrity Patients with a history of somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study Patients with symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression Patients who received transfusion for the sole purpose of making a subject eligible for study inclusion